SCHEMBL7184548

SCHEMBL7184548

COc1ccc(PC(=O)c2c(C)cc(C)cc2C)c(C)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
CYP3A4 P08684 3/20 0.39
HPGD P15428 3/20 0.39
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
TSPO P30536 1/20 0.36
FLT3 P36888 1/20 0.36
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182499 0.89 KMT2A (0.41) ALDH1A1CYP3A4L3MBTL1LMNAMAPK1
SCHEMBL7180900 0.88 MEN1 (0.41) ALDH1A1CYP3A4HPGDHTTL3MBTL1
SCHEMBL7189379 0.87 MAPT (0.38) ALDH1A1CYP3A4HPGDHTTL3MBTL1
Lithium SCHEMBL7182503 0.86 KMT2A (0.41) ALDH1A1CYP3A4L3MBTL1LMNAMAPK1
SCHEMBL7182015 0.86 FFAR4 (0.41) ALDH1A1HPGDLMNAFFAR4TSPO
SCHEMBL7178301 0.86 CYP3A4 (0.37) ALDH1A1CYP3A4HPGDHTTLMNA
SCHEMBL7175989 0.85 ALDH1A1 (0.39) ALDH1A1HPGDHTTL3MBTL1LMNA
SCHEMBL7174738 0.85 KDM4E (0.31) ALDH1A1L3MBTL1
SCHEMBL7185525 0.84 TP53 (0.36) ALDH1A1HPGDHTTL3MBTL1LMNA
SCHEMBL7187558 0.84 KMT2A (0.48) ALDH1A1CYP3A4HTTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885CYP3A4 1652/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885CYP3A4 1881/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.